Skip to main
FBLG
FBLG logo

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. is showing a promising trajectory in its clinical development of fibroblast-based therapies owing to its progress in preclinical IND-enabling studies and the scalable production potential of its fibroblast spheroid candidates. The company's focus on addressing chronic diseases with unmet medical needs is supported by a robust intellectual property estate and efficient operating practices, despite rising expenses associated with development scale-up. Positive early results in wound healing and ongoing advancements in treatments for chronic-relapse psoriasis and multiple sclerosis indicate substantial upside potential, reinforcing an optimistic outlook for the company’s financial future.

Bears say

FibroBiologics Inc is facing significant financial challenges that contribute to a negative outlook on its stock. The company reported a net loss of $5.8 million for Q3 2025, and the stock has plummeted over 80% year-to-date, contrasting sharply with overall market growth reflected in the NBI, which is up over 20%. Furthermore, concerns regarding the company's ability to secure necessary capital, achieve projected commercial revenues, and effectively manage R&D expenses amid widening losses add to the uncertainties about its future potential.

Fibrobiologics Inc (FBLG) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.